Epsilogen Announces Completion of Oversubscribed £30.75 Million ($41.20 Million) Series B Financing
Epsilogen Ltd, a global leader in the development of novel immunoglobulin E (IgE) antibodies to treat cancer, announced it has secured £30.75 million ($41.20 million) in an…
Read More...
Read More...